M28 Capital Management’s ProQR Therapeutics PRQR Stock Holding History

M28 Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$972K	Sell	599,793 -419,705	-41%	-$688K	1.81%	5
2025 Q4	$2.06M	Hold	1,019,498	–	–	1.5%	6
2025 Q3	$2.17M	Hold	1,019,498	–	–	3.19%	6
2025 Q2	$2.08M	Hold	1,019,498	–	–	3.55%	5
2025 Q1	$1.36M	Hold	1,019,498	–	–	1.86%	8
2024 Q4	$2.7M	Hold	1,019,498	–	–	2.65%	8
2024 Q3	$1.86M	Hold	1,019,498	–	–	2.04%	10
2024 Q2	$1.69M	Hold	1,019,498	–	–	2.19%	11
2024 Q1	$2.33M	Sell	1,019,498 -891,102	-47%	-$1.91M	1.73%	10
2023 Q4	$3.78M	Hold	1,910,600	–	–	3.13%	8
2023 Q3	$2.48M	Hold	1,910,600	–	–	2.85%	8
2023 Q2	$3.1M	Hold	1,910,600	–	–	4.09%	8
2023 Q1	$4.07M	Hold	1,910,600	–	–	4.6%	9
2022 Q4	$7.07M	Buy	1,910,600 +908,800	+91%	+$1.19M	6.74%	4
2022 Q3	$745K	Hold	1,001,800	–	–	0.78%	11
2022 Q2	$779K	Hold	1,001,800	–	–	0.87%	12
2022 Q1	$907K	Buy	+1,001,800	New	+$3.36M	0.83%	12

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

M28 Capital Management's PRQR Position: Q1 2026 in Review

M28 Capital Management reduced its ProQR Therapeutics (PRQR) stake by 41% in Q1 2026, selling an estimated $688K and leaving 599,793 shares worth $972K. The position accounts for 1.81% of the portfolio, ranked #5.

M28 Capital Management first reported a position in PRQR in Q1 2022 and has held it in 17 quarters since. The position peaked at $7.07M in Q4 2022. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

M28 Capital Management held 599,793 shares of ProQR Therapeutics worth $972K as of Q1 2026.
M28 Capital Management sold 419,705 ProQR Therapeutics shares in Q1 2026, an estimated $688K.
ProQR Therapeutics made up 1.81% of M28 Capital Management's portfolio in Q1 2026, its #5 holding.
M28 Capital Management first reported a position in ProQR Therapeutics in Q1 2022 and has held it in 17 quarters since.
M28 Capital Management's ProQR Therapeutics position peaked at $7.07M in Q4 2022.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on M28 Capital Management's 13F filing for Q1 2026, filed 14 May 2026.